$11.74
3.53% (Daily)
Market Cap
$838.36M
Revenue
$150.13M
Rank by MCap
#1762
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Bassil I. Dahiyat Ph.D.
Headquarters
Pasadena, CA
Employees
250
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab...
Loading chart…